Humasis

Market position

Humasis is described as an established South Korean IVD and POCT manufacturer that gained wider international recognition during the COVID-19 pandemic through rapid antigen tests carrying FDA Emergency Use Authorization and CE marking. Third-party classification places it as a challenger against competitors including SD Biosensor, Seegene, Abbott Laboratories, QuidelOrtho and Roche Diagnostics.

Humasis positions its strengths around in-house POCT original technologies and specialized research teams, a broad product range covering early detection, prevention and disease management, in-house production of diagnostic immune antigen raw materials to maintain kit consistency, and combined system/service development capability spanning healthcare solutions, mobile diagnosis for remote care, artificial intelligence, LIS and HIS integration.

Technology

Core technology is lateral flow immunoassay-based rapid diagnostics and POCT instrumentation, with in-house development of diagnostic immune antigen raw materials. Instruments such as HUBI-QUAN Pro and HUBI-TAS provide quantitative analysis of up to six markers within 15 minutes from small blood volumes, with a multi-tray option for concurrent tests. Software capabilities include analysis algorithms, real-time monitoring of deployed analyzers, LIMS-based process and quality control, CRM with remote diagnostics, and AI-based smart healthcare apps; third-party data also lists molecular diagnostics among its modalities.

Go-to-market

Humasis sells its diagnostic kits and instruments internationally through client relationships across 74 countries and has pursued localization via overseas subsidiaries, including a wholly owned U.S. entity intended to increase contact with local clients, obtain FDA approvals for key products and raise brand awareness in the U.S. market. Regulatory clearances (CE marking, ISO certification, Korean MFDS approval, Health Canada CE-self-testing) underpin market access, and third-party data cites partnerships with Celltrion on COVID-19 tests and with NGOs for malaria and dengue screening.

Hospitals, clinics and point-of-care and emergency screening settings, distributors and clients in 74 export markets, public health and NGO screening programs, and consumers using self-test products such as pregnancy, ovulation and COVID-19 home tests.

Geography

Headquartered in South Korea, with a reported location in Anyang-si and a Wellness R&D Center office in Gunpo-si, Gyeonggi-do. Products are exported to 74 countries, and third-party profile data lists subsidiaries in Vietnam (Humasis Vina), the United States and Zimbabwe. A U.S. subsidiary was approved in 2021 to address the North American market.

History

Humasis was established in 2000 and built out research and manufacturing capability over the following two decades. Its Central R&D Center was created in the 2000s, alongside ISO 9001, ISO 13485 and CE certifications and European CE certificates for cardiac markers such as CK-MB and myoglobin. Between 2010 and 2019 it obtained production permits for the HUBI TESTO and HUBI-IL6 devices and CE certificates for urinalysis systems and a self-test pregnancy kit. From 2020 the company added COVID-19 products, including CE-marked antigen home tests and IgG/IgM tests and a Ministry of Food and Drug Safety-approved COVID-19/Flu antigen combo test, and reported exports of $30 million in 2021. In 2021 its board approved a $2 million wholly owned U.S. subsidiary to pursue FDA approvals and North American distribution.